MAL2

Summary

MAL2 (mal, T cell differentiation protein 2, HGNC:13634) is a protein-coding gene on chromosome 8q24.12, encoding Protein MAL2 (Q969L2). Member of the machinery of polarized transport.

This gene encodes a multispan transmembrane protein belonging to the MAL proteolipid family. The protein is a component of lipid rafts and, in polarized cells, it primarily localizes to endosomal structures beneath the apical membrane. It is required for transcytosis, an intracellular transport pathway used to deliver membrane-bound proteins and exogenous cargos from the basolateral to the apical surface.

Source: NCBI Gene 114569 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 23 total
• Druggable target: yes
• MANE Select transcript: NM_052886

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13634
Approved symbol	MAL2
Name	mal, T cell differentiation protein 2
Location	8q24.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000147676
Ensembl biotype	protein_coding
OMIM	609684
Entrez	114569

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000522112, ENST00000531508, ENST00000534619, ENST00000614891, ENST00000884402, ENST00000884403, ENST00000884404

RefSeq mRNA: 1 — MANE Select: NM_052886 NM_052886

CCDS: CCDS75780

Canonical transcript exons

ENST00000614891 — 4 exons

Exon	Start	End
ENSE00003541887	119240165	119240320
ENSE00003726109	119208363	119208604
ENSE00003731759	119221587	119221757
ENSE00003749627	119243417	119245673

Expression profiles

Bgee: expression breadth ubiquitous, 231 present calls, max score 99.61.

FANTOM5 (CAGE): breadth broad, TPM avg 31.0406 / max 1045.4489, expressed in 790 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
90377	22.6055	755
90378	6.0949	669
90387	0.8131	382
90382	0.6391	223
90380	0.2883	193
90388	0.2505	128
90381	0.1534	84
90379	0.1043	43
90376	0.0809	40
90375	0.0107	3

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	99.61	gold quality
esophagus squamous epithelium	UBERON:0006920	99.60	gold quality
oral cavity	UBERON:0000167	99.37	gold quality
pharyngeal mucosa	UBERON:0000355	99.26	gold quality
nasal cavity epithelium	UBERON:0005384	99.18	gold quality
amniotic fluid	UBERON:0000173	99.09	gold quality
palpebral conjunctiva	UBERON:0001812	99.01	gold quality
lower esophagus mucosa	UBERON:0035834	98.97	gold quality
penis	UBERON:0000989	98.94	gold quality
gingiva	UBERON:0001828	98.91	gold quality
colonic mucosa	UBERON:0000317	98.75	gold quality
mucosa of sigmoid colon	UBERON:0004993	98.71	gold quality
gingival epithelium	UBERON:0001949	98.70	gold quality
ileal mucosa	UBERON:0000331	98.69	gold quality
mammalian vulva	UBERON:0000997	98.63	gold quality
bronchial epithelial cell	CL:0002328	98.52	gold quality
kidney epithelium	UBERON:0004819	98.43	gold quality
bronchus	UBERON:0002185	98.39	gold quality
upper leg skin	UBERON:0004262	98.34	gold quality
esophagus mucosa	UBERON:0002469	98.27	gold quality
renal medulla	UBERON:0000362	98.21	gold quality
rectum	UBERON:0001052	97.77	gold quality
skin of hip	UBERON:0001554	97.73	gold quality
islet of Langerhans	UBERON:0000006	97.65	gold quality
epithelium of nasopharynx	UBERON:0001951	97.53	gold quality
nasal cavity mucosa	UBERON:0001826	97.33	gold quality
jejunal mucosa	UBERON:0000399	97.29	gold quality
oviduct epithelium	UBERON:0004804	97.08	gold quality
body of tongue	UBERON:0011876	97.08	gold quality
tongue	UBERON:0001723	97.06	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-10283	yes	810.91
E-MTAB-8559	yes	489.75
E-MTAB-10662	yes	398.56
E-CURD-114	yes	321.33
E-HCAD-1	yes	225.23
E-MTAB-6819	yes	214.67
E-MTAB-8142	yes	118.24
E-MTAB-8410	yes	50.00
E-HCAD-10	yes	24.52
E-GEOD-125970	yes	23.99
E-MTAB-9388	yes	12.81
E-MTAB-8271	yes	7.77
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

154 targeting MAL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 17)

• Data show that MAL2 is essential for transcytosis in HepG2 cells. (PMID:12370246)
• MAL2 protein mRNA species were detected in the thyroid and immunohistochemical analysis of thyroid follicles indicated that MAL2 distributed to the apical membrane (PMID:14576188)
• The results indicate that MAL2 protein genes are not ubiquitously expressed in leukemic bone marrow in children, and that RNA sample parameters may influence measures of gene expression more than commonly appreciated. (PMID:16620967)
• The MAL2 gene was shown to effectively separate these two tumor(chromophobe renal cell carcinoma (RCC) and benign oncocytoma) groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues. (PMID:17145811)
• a role for MAL2 in regulating tumor-associated protein mucin expression and/or localisation (PMID:19175940)
• after differentiation, murine oligodendrocyte precursor and human oligodendroglioma derived cell lines up-regulate the expression of MAL2 and accumulate it in an intracellular compartment, exhibiting a peri-centrosomal localization. (PMID:19683524)
• MAL2 overexpression was highest in serous carcinomas relative to other histological subtypes of ovarian cancer. (PMID:20846453)
• Results prove for the first time the interaction of PLP and MAL2 in oligodendrocytic cells, supporting the transcytotic model of PLP transport previously suggested. (PMID:21573057)
• MAL2 and STK16 function to sort secretory soluble cargo into the constitutive secretory pathway in hepatocytes. (PMID:25084525)
• data suggested that MAL2 and TPD52 might be potential biomarkers for clinical prognosis and might be a promising therapeutic target for CRC (PMID:28562687)
• Up-regulation of MAL2 was hound in papillary thyroid gland tissues and significantly correlated with poor overall survival. (PMID:30021343)
• MAL2 has a role in promoting proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines (PMID:30195491)
• RP11-284F21.9 knockdown could reduce MAL2 expression, while miR-383-5p inhibitors abolished this repressive effect (PMID:31397491)
• MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. (PMID:32990678)
• MAL2 interacts with IQGAP1 to promote pancreatic cancer progression by increasing ERK1/2 phosphorylation. (PMID:33780861)
• The novel circ_0084904/miR-802/MAL2 axis promotes the development of cervical cancer. (PMID:35033901)
• LINC00460 Facilitates Cell Proliferation and Inhibits Ferroptosis in Breast Cancer Through the miR-320a/MAL2 Axis. (PMID:36938678)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mal2	ENSDARG00000077637
mus_musculus	Mal2	ENSMUSG00000024479
rattus_norvegicus	Mal2	ENSRNOG00000008615
caenorhabditis_elegans	F28H1.4	WBGENE00017909
caenorhabditis_elegans	F47B3.3	WBGENE00018527

Paralogs (14): CMTM1 (ENSG00000089505), CMTM6 (ENSG00000091317), PLP2 (ENSG00000102007), PLLP (ENSG00000102934), CMTM3 (ENSG00000140931), CMTM2 (ENSG00000140932), MALL (ENSG00000144063), CMTM7 (ENSG00000153551), MARVELD1 (ENSG00000155254), CMTM5 (ENSG00000166091), CMTM8 (ENSG00000170293), MAL (ENSG00000172005), CMTM4 (ENSG00000183723), CKLF (ENSG00000217555)

Protein

Protein identifiers

Protein MAL2 — Q969L2 (reviewed: Q969L2)

All UniProt accessions (2): Q969L2, A0A087WZL1

UniProt curated annotations — full annotation on UniProt →

Function. Member of the machinery of polarized transport. Required for the indirect transcytotic route at the step of the egress of the transcytosing cargo from perinuclear endosomes in order for it to travel to the apical surface via a raft-dependent pathway.

Subunit / interactions. Interacts with TPD52L2.

Subcellular location. Cell membrane. Apical cell membrane. Endomembrane system. Cytoplasm. Perinuclear region.

Tissue specificity. Predominantly expressed in kidney, lung, and liver. Also found in thyroid gland, stomach and, at lower levels in testis and small intestine.

Similarity. Belongs to the MAL family.

RefSeq proteins (1): NP_443118* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008253	Marvel	Domain
IPR013295	MAL	Family
IPR050578	MARVEL-CKLF_proteins	Family

Pfam: PF01284

UniProt features (13 total): topological domain 5, transmembrane region 4, chain 1, domain 1, glycosylation site 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969L2-F1	85.42	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 132

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 133 (showing top): MODULE_255, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, MODULE_317, PATIL_LIVER_CANCER, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, GOBP_ENSHEATHMENT_OF_NEURONS, ACATTCC_MIR1_MIR206, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOCC_APICAL_PLASMA_MEMBRANE, AIGNER_ZEB1_TARGETS, POU3F2_02, CART1_01, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, MODULE_342, NUYTTEN_EZH2_TARGETS_DN

GO Biological Process (1): myelination (GO:0042552)

GO Molecular Function (2): structural constituent of myelin sheath (GO:0019911), protein binding (GO:0005515)

GO Cellular Component (8): endomembrane system (GO:0012505), membrane (GO:0016020), apical plasma membrane (GO:0016324), membrane raft (GO:0045121), perinuclear region of cytoplasm (GO:0048471), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), plasma membrane (GO:0005886)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
axon ensheathment	1
structural molecule activity	1
myelin sheath	1
binding	1
vacuole	1
plasma membrane	1
apical part of cell	1
plasma membrane region	1
membrane microdomain	1
cytoplasm	1
extracellular vesicle	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1054 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAL2	TPD52L2	O43399	923
MAL2	TPD52	P55327	890
MAL2	PIGR	P01833	695
MAL2	CD59	P13987	652
MAL2	OCLN	Q16625	600
MAL2	CENPI	Q92674	576
MAL2	CHD7	Q9P2D1	570
MAL2	RAB11A	P24410	557
MAL2	MARCHF2	Q9P0N8	529
MAL2	CENPK	Q9BS16	523
MAL2	INF2	Q27J81	519
MAL2	ITIH2	P19823	494
MAL2	MALL	Q13021	455
MAL2	CENPN	Q96H22	451
MAL2	KRT19	P08727	445

IntAct

200 interactions, top by confidence:

A	B	Type	Score
MAL2	ARFIP2	psi-mi:“MI:0915”(physical association)	0.720
MAL2	GAD2	psi-mi:“MI:0915”(physical association)	0.720
GAD2	MAL2	psi-mi:“MI:0915”(physical association)	0.720
GAD1	MAL2	psi-mi:“MI:0915”(physical association)	0.720
NDRG4	MAL2	psi-mi:“MI:0915”(physical association)	0.720
MAL2	NDRG4	psi-mi:“MI:0915”(physical association)	0.720
MAL2	SH3GLB1	psi-mi:“MI:0915”(physical association)	0.720
MAL2	GAD1	psi-mi:“MI:0915”(physical association)	0.720
ARFIP2	MAL2	psi-mi:“MI:0915”(physical association)	0.720
SH3GLB1	MAL2	psi-mi:“MI:0915”(physical association)	0.720
PTPN9	MAL2	psi-mi:“MI:0915”(physical association)	0.670
MAL2	PTPN9	psi-mi:“MI:0915”(physical association)	0.670
MAL2	PBX3	psi-mi:“MI:0915”(physical association)	0.560
VARS2	MAL2	psi-mi:“MI:0915”(physical association)	0.560
TUBB	MAL2	psi-mi:“MI:0915”(physical association)	0.560
SH3GL1	MAL2	psi-mi:“MI:0915”(physical association)	0.560
MAL2	PTPN9	psi-mi:“MI:0915”(physical association)	0.560
MAL2	TBRG4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (73): MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), TUBB (Two-hybrid), RAB37 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid), MAL2 (Two-hybrid)

ESM2 similar proteins: A2VE13, A4K2N5, A4K2W1, B8BPI2, E1BY51, O09117, O09198, O35682, O62646, O88662, O89104, P21145, Q04941, Q10EJ2, Q16563, Q1RMQ3, Q28296, Q3URJ8, Q3ZBY0, Q5R6H1, Q5RAI2, Q5VXT5, Q64349, Q6DHB5, Q6GPN9, Q6P0C6, Q6P742, Q6VBQ5, Q6Y1E2, Q78S06, Q86TG1, Q86UW1, Q8BI08, Q8CJ61, Q8IZ96, Q8IZR5, Q8N2H4, Q8N8D7, Q91WN2, Q95MN6

Diamond homologs: A2VE13, A3KQ86, O09198, P21145, Q13021, Q28296, Q3ZBY0, Q5RAI2, Q64349, Q6GPN9, Q8BI08, Q91X49, Q969L2, Q9CZR4, P47987, Q1RMP9, Q8IZV2, Q9DCU2, Q9Y342, A6H7B0, Q5BLB7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	11
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

655 predictions. Top by Δscore:

Variant	Effect	Δscore
8:119208601:GATT:G	donor_gain	1.0000
8:119208603:TT:T	donor_gain	1.0000
8:119208605:G:GG	donor_gain	1.0000
8:119240162:TAG:T	acceptor_loss	1.0000
8:119240163:AGG:A	acceptor_loss	1.0000
8:119240164:G:GA	acceptor_loss	1.0000
8:119240317:CTCA:C	donor_gain	1.0000
8:119240318:TCA:T	donor_gain	1.0000
8:119240321:G:GG	donor_gain	1.0000
8:119208600:AGATT:A	donor_gain	0.9900
8:119208601:GATTG:G	donor_gain	0.9900
8:119208602:ATT:A	donor_gain	0.9900
8:119208602:ATTGT:A	donor_loss	0.9900
8:119208604:TGTA:T	donor_loss	0.9900
8:119208605:G:C	donor_loss	0.9900
8:119208606:TAAG:T	donor_loss	0.9900
8:119221585:A:AG	acceptor_gain	0.9900
8:119221586:G:GA	acceptor_gain	0.9900
8:119221586:GCT:G	acceptor_gain	0.9900
8:119221755:CTGG:C	donor_loss	0.9900
8:119221757:GGTA:G	donor_loss	0.9900
8:119221758:G:A	donor_loss	0.9900
8:119221759:TAA:T	donor_loss	0.9900
8:119240163:A:AG	acceptor_gain	0.9900
8:119240163:AG:A	acceptor_gain	0.9900
8:119240164:G:GG	acceptor_gain	0.9900
8:119240164:GG:G	acceptor_gain	0.9900
8:119240203:T:TA	acceptor_gain	0.9900
8:119240316:CCTCA:C	donor_gain	0.9900
8:119240318:TCAGT:T	donor_loss	0.9900

AlphaMissense

1125 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:119221605:T:A	W51R	0.996
8:119221605:T:C	W51R	0.996
8:119221653:T:A	W67R	0.995
8:119221653:T:C	W67R	0.995
8:119243453:A:C	S166R	0.994
8:119243455:T:A	S166R	0.994
8:119243455:T:G	S166R	0.994
8:119243441:T:C	C162R	0.991
8:119240316:C:A	A152D	0.989
8:119208599:G:A	E43K	0.988
8:119221594:G:A	G47E	0.988
8:119243448:G:A	G164D	0.988
8:119208593:T:C	C41R	0.987
8:119221669:C:A	S72Y	0.985
8:119243450:T:C	C165R	0.985
8:119208581:G:C	G37R	0.984
8:119221615:T:A	V54D	0.984
8:119243436:C:A	T160K	0.984
8:119243447:G:C	G164R	0.984
8:119221669:C:T	S72F	0.983
8:119221746:T:A	W98R	0.982
8:119221746:T:C	W98R	0.982
8:119208600:A:T	E43V	0.981
8:119240315:G:C	A152P	0.981
8:119221593:G:A	G47R	0.980
8:119221593:G:C	G47R	0.980
8:119221618:C:A	A55D	0.980
8:119221655:G:C	W67C	0.980
8:119221655:G:T	W67C	0.980
8:119240204:G:A	G115R	0.980

dbSNP variants (sampled 300 via entrez): RS1000032168 (8:119216636 C>T), RS1000064212 (8:119235610 C>G,T), RS1000087977 (8:119226506 G>A,C,T), RS1000106701 (8:119216416 C>T), RS1000139935 (8:119222834 A>G), RS1000284380 (8:119222482 C>T), RS1000301155 (8:119243283 T>A,C,G), RS1000354910 (8:119240599 CAA>C,CAAA), RS1000517732 (8:119217221 C>T), RS1000565028 (8:119242159 A>G), RS1000637119 (8:119241954 G>A), RS1000741431 (8:119245627 A>G), RS1000936943 (8:119232509 A>G), RS1001228567 (8:119245020 T>A), RS1001300969 (8:119240550 A>G)

Disease associations

OMIM: gene MIM:609684 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000461_5	Hippocampal atrophy	9.000000e-06
GCST002546_1	Osteoprotegerin levels	8.000000e-15
GCST002546_4	Osteoprotegerin levels	8.000000e-09
GCST002587_13	Blood pressure (smoking interaction)	2.000000e-07
GCST002587_14	Blood pressure (smoking interaction)	4.000000e-06
GCST007209_13	Gallstone disease	9.000000e-12
GCST90011899_152	Aspartate aminotransferase levels	6.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005039	hippocampal atrophy
EFO:0006335	systolic blood pressure
EFO:0006526	pack-years measurement
EFO:0006525	cigarettes per day measurement
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067291 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.75	Kd	176.6	nM	CHEMBL3752910
6.75	ED50	176.6	nM	CHEMBL3752910
5.77	Kd	1683	nM	CHEMBL5653589
5.77	ED50	1683	nM	CHEMBL5653589

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148682: Binding affinity to human MAL2 incubated for 45 mins by Kinobead based pull down assay	kd	0.1766	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148682: Binding affinity to human MAL2 incubated for 45 mins by Kinobead based pull down assay	kd	1.6829	uM

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
trichostatin A	affects cotreatment, increases expression	3
Acetaminophen	decreases expression, increases expression	3
sodium arsenite	decreases expression, increases expression	2
potassium chromate(VI)	increases expression, affects cotreatment, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
bisphenol A	increases expression	1
lead acetate	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cupric chloride	decreases expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
chromium hexavalent ion	affects expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Arsenic	decreases expression, increases abundance	1
Azathioprine	decreases expression	1
Caffeine	decreases phosphorylation	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651724	Binding	Binding affinity to human MAL2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.